Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Estudio de fase 1/2 del inhibidor de RET oral LOXO 292 en pacientes pediátricos con tumores sólidos avanzados o tumores primario

Estudio de fase 1/2 del inhibidor de RET oral LOXO 292 en pacientes pediátricos con tumores sólidos avanzados o tumores primarios del sistema nervioso central ambos con alteración de RET.

Contact
  • Protocol code: LOXO-RET-18036 (292036) J2G-OX-JZJJ
  • EudraCT code: 2019-000212-28
  • Pathology: Tumores sólidos o primarios del sistema nervioso central con alteración avanzada de RET
  • Pharmac: Oral RET Inhibitor LOXO-292
  • Promoter: Eli Lilly
  • Principal investigator:  Hladun Alvaro, Raquel
  • Research group:  Càncer i malalties hematològiques infantils
  • Service: Oncohematologia Pediàtrica
  • Phase: Fase I
  • Recruiting: Closed
  • Status: Finalizado

Contact Form

I have read and accept the data protection policy *.

Controller: Fundació Hospital Universitari Vall Hebron Institut de Recerca – VHIR- G60594009.
Purpose: Request for information on VHIR clinical research.
Legitimation: Your consent. The data requested is necessary and your request cannot be processed if you do not provide them.
Transfers: Your data will not be transferred to third parties except to the Principal Investigator who leads the research in order to be able to respond to your query.
Data retention time: As long as they are useful for the purpose for which they were collected and responsibilities may arise.
Rights: You can access, rectify, delete your data, oppose or limit its processing and request its portability, as well as revoke your consent without retroactive effects by contacting lopd@vhir.org. The revocation of consent and the opposition to the processing of your data will prevent the purpose from being carried out. DPO: dpd@ticsalutsocial.org. More information 
The request for information on a research project or clinical trial does not entail inclusion in it.